MBOT
Price
$1.81
Change
-$0.04 (-2.16%)
Updated
Jun 23, 04:10 PM (EDT)
Capitalization
124.25M
56 days until earnings call
Intraday BUY SELL Signals
RCEL
Price
$3.92
Change
-$0.11 (-2.73%)
Updated
Jun 23, 04:15 PM (EDT)
Capitalization
124.34M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MBOT vs RCEL

MBOT vs RCEL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MBOT vs. RCEL commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Buy and RCEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (MBOT: $1.85 vs. RCEL: $4.04)
Brand notoriety: MBOT and RCEL are both not notable
MBOT represents the Pharmaceuticals: Other, while RCEL is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: MBOT: 71% vs. RCEL: 89%
Market capitalization -- MBOT: $124.25M vs. RCEL: $124.34M
MBOT [@Pharmaceuticals: Other] is valued at $124.25M. RCEL’s [@Medical/Nursing Services] market capitalization is $124.34M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $142.71B to $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $152.98B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $7.5B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBOT’s FA Score shows that 0 FA rating(s) are green whileRCEL’s FA Score has 0 green FA rating(s).

  • MBOT’s FA Score: 0 green, 5 red.
  • RCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, MBOT is a better buy in the long-term than RCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBOT’s TA Score shows that 5 TA indicator(s) are bullish while RCEL’s TA Score has 3 bullish TA indicator(s).

  • MBOT’s TA Score: 5 bullish, 2 bearish.
  • RCEL’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, MBOT is a better buy in the short-term than RCEL.

Price Growth

MBOT (@Pharmaceuticals: Other) experienced а +1.65% price change this week, while RCEL (@Medical/Nursing Services) price change was +2.80% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.31%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was -14.76%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.

Reported Earning Dates

MBOT is expected to report earnings on Aug 18, 2026.

RCEL is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-2.31% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical/Nursing Services (-0.22% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MBOT($124M) and RCEL($124M) have the same market capitalization . RCEL YTD gains are higher at: 17.101 vs. MBOT (-7.500). MBOT has higher annual earnings (EBITDA): -16M vs. RCEL (-37.7M). MBOT has more cash in the bank: 72.5M vs. RCEL (14.3M). MBOT has less debt than RCEL: MBOT (898K) vs RCEL (48.1M). RCEL has higher revenues than MBOT: RCEL (72.3M) vs MBOT (105K).
MBOTRCELMBOT / RCEL
Capitalization124M124M100%
EBITDA-16M-37.7M42%
Gain YTD-7.50017.101-44%
P/E RatioN/AN/A-
Revenue105K72.3M0%
Total Cash72.5M14.3M507%
Total Debt898K48.1M2%
FUNDAMENTALS RATINGS
MBOT vs RCEL: Fundamental Ratings
MBOT
RCEL
OUTLOOK RATING
1..100
2569
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6259
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MBOT's Valuation (45) in the Biotechnology industry is in the same range as RCEL (53) in the null industry. This means that MBOT’s stock grew similarly to RCEL’s over the last 12 months.

MBOT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RCEL (100) in the null industry. This means that MBOT’s stock grew similarly to RCEL’s over the last 12 months.

MBOT's SMR Rating (98) in the Biotechnology industry is in the same range as RCEL (100) in the null industry. This means that MBOT’s stock grew similarly to RCEL’s over the last 12 months.

RCEL's Price Growth Rating (59) in the null industry is in the same range as MBOT (62) in the Biotechnology industry. This means that RCEL’s stock grew similarly to MBOT’s over the last 12 months.

RCEL's P/E Growth Rating (100) in the null industry is in the same range as MBOT (100) in the Biotechnology industry. This means that RCEL’s stock grew similarly to MBOT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBOTRCEL
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 26 days ago
72%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MBOT
Daily Signal:
Gain/Loss:
RCEL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MFQTX15.98N/A
N/A
AMG Veritas Global Focus I
HCMPX21.72N/A
N/A
HCM Sector Plus Investor
PGBEX38.15N/A
N/A
Principal Blue Chip R3
TCGRX36.56N/A
N/A
Thornburg Focus Growth R4
PWITX21.27N/A
N/A
PACE International Equity Invmt P2

MBOT and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with AGPU. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then AGPU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
-0.54%
AGPU - MBOT
37%
Loosely correlated
+0.28%
RCEL - MBOT
33%
Poorly correlated
+0.75%
AIMD - MBOT
32%
Poorly correlated
+3.11%
CODX - MBOT
31%
Poorly correlated
-7.42%
NNOX - MBOT
30%
Poorly correlated
-2.99%
More

RCEL and

Correlation & Price change

A.I.dvisor tells us that RCEL and MBOT have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RCEL and MBOT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCEL
1D Price
Change %
RCEL100%
+0.75%
MBOT - RCEL
33%
Poorly correlated
-0.54%
NTRA - RCEL
30%
Poorly correlated
-1.13%
SGHT - RCEL
30%
Poorly correlated
-0.76%
VCYT - RCEL
29%
Poorly correlated
-0.82%
TWST - RCEL
29%
Poorly correlated
-2.91%
More